China Pharma Holdings, Inc. (CPHI) vs SCYNEXIS, Inc. (SCYX)

China Pharma Holdings, Inc. and SCYNEXIS, Inc. are both Drug Manufacturers Specialty & Generic companies. SCYNEXIS, Inc. is the larger, with a market value of $45.0M against $31.8M — 1.4× the size. SCYNEXIS, Inc. grew revenue faster over the last twelve months: 682.5% against −11.0%. SCYNEXIS, Inc. has the higher net margin (−49.7% vs −114.3%) and the lower return on invested capital (−110.7% vs −7.23%). Across the 18 metrics below, SCYNEXIS, Inc. leads on 13 and China Pharma Holdings, Inc. on 5.

Valuation

Metric CPHI SCYX Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 7.76 2.52 2.25
P/B 0.84 0.78 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 8.52 1.15 2.56
Earnings yield (57.33%) (47.61%) (2.99%)
Free cash flow yield (1.10%) (25.67%) 0.00%

Profitability

Metric CPHI SCYX Drug Manufacturers Specialty & Generic median
Gross margin 11.76% 100.00% 53.94%
Operating margin (111.84%) (109.90%) 0.00%
Net margin (114.33%) (49.74%) 0.00%
Free cash flow margin (3.59%) (64.67%) 0.00%
Return on equity (20.99%) (18.38%) (0.40%)
Return on assets (15.30%) (15.09%) (3.32%)
Return on invested capital (7.23%) (110.72%) 0.00%

Growth

Metric CPHI SCYX Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (10.97%) 682.47% 10.01%
EPS growth (last fiscal year) 72.59% 61.36% —
Revenue growth, 5-year CAGR (17.53%) 179.40% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CPHI SCYX Drug Manufacturers Specialty & Generic median
Debt to equity 0.05 0.00 0.05
Current ratio 0.26 9.65 2.31
Net debt to EBITDA (0.98) 2.54 0.85

Dividend

Metric CPHI SCYX Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric CPHI SCYX Drug Manufacturers Specialty & Generic median
Market cap 31.83m 44.98m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack